Brief: Sagimet Biosciences Announces Positive Topline Results From Phase 2B Fascinate-2 Clinical Trial Of Denifanstat In Biopsy-Confirmed F2/F3 Nash
22/01/2024 12:30
Jan 22 (Reuters) - Sagimet Biosciences Inc SGMT.O :
* SAGIMET BIOSCIENCES ANNOUNCES POSITIVE TOPLINE
RESULTS FROM
PHASE 2B FASCINATE-2 CLINICAL TRIAL OF DENIFANSTAT
IN BIOPSY-CONFIRMED F2/F3 NASH
* SAGIMET BIOSCIENCES INC: DENIFANSTAT WAS GENERALLY
WELL-TOLERATED
* SAGIMET BIOSCIENCES INC - DENIFANSTAT ACHIEVED
STATISTICALLY
SIGNIFICANT RESULTS ON PRIMARY AND MULTIPLE SECONDARY ENDPOINTS
* SAGIMET BIOSCIENCES INC - NO TREATMENT-RELATED SERIOUS
ADVERSE
EVENTS (SAES) WERE OBSERVED
* SAGIMET BIOSCIENCES INC: WILL HOLD AN END-OF-PHASE 2
MEETING
WITH FDA AND START OUR PHASE 3 PROGRAM, ANTICIPATED TO BEGIN IN
SECOND HALF OF 2024
Source text for Eikon: ID:nGNX5Yd942
Further company coverage: SGMT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sagimet Biosciences
See all newsBrief: Sagimet Biosciences Announces Pricing Of $115.0 Million Underwritten Offering Of Series A Common Stock And Pre-Funded Warrants
Brief: Sagimet Biosciences - Suspends And Terminates ATM Prospectus Supplement For Series A Common Stock Effective Sept 30
Brief: Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial Of Denifanstat In Acne Toward Patient Enrollment In Q4 2026
Brief: Sagimet Biosciences Phase 3 Clinical Trial Is On Track To Initiate In Second Half Of 2026
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage